31595-63-8

Basic information

• Product Name: 2,3-Quinoxalinedione,1,4-dihydro-,monohydrazone(9CI)
• Synonyms: 2,3-Quinoxalinedione,1,4-dihydro-,monohydrazone(9CI);3-HYDRAZONO-3,4-DIHYDROQUINOXALIN-2(1H)-ONE;2-quinoxalinol, 3-hydrazino-;3-hydrazinoquinoxalin-2-ol(SALTDATA: FREE);3-Hydrazinylquinoxalin-2-ol;3-hydrazino-1H-quinoxalin-2-one;3-hydrazinyl-1H-quinoxalin-2-one
• CAS NO: 31595-63-8
• Molecular Formula: C₈H₈N₄O
• Molecular Weight: 176.18
• Product Categories: PIPERIDINE
• Mol File: 31595-63-8.mol
• Article Data: 2

Chemical Properties

• Melting Point: >300 °C
• Boiling Point: 458.8°C at 760 mmHg
• Flash Point: 231.3°C
• Appearance: /
• Density: 1.56g/cm³
• Vapor Pressure: 4.87E-09mmHg at 25°C
• Refractive Index: 1.758
• PKA: 9.84±0.20(Predicted)
• CAS DataBase Reference: 2,3-Quinoxalinedione,1,4-dihydro-,monohydrazone(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Quinoxalinedione,1,4-dihydro-,monohydrazone(9CI)(31595-63-8)
• EPA Substance Registry System: 2,3-Quinoxalinedione,1,4-dihydro-,monohydrazone(9CI)(31595-63-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 31595-63-8(Hazardous Substances Data)

Usage

General Description

2,3-Quinoxalinedione,1,4-dihydro-,monohydrazone(9CI) is a chemical compound with the molecular formula C8H10N2O2. It is a hydrazone derivative of 2,3-quinoxalinedione and is commonly used in organic synthesis and pharmaceutical research. 2,3-Quinoxalinedione,1,4-dihydro-,monohydrazone(9CI) has a solid state appearance and is typically used as a reactant in various chemical reactions. Its unique structure and properties make it suitable for use in the development of new drug compounds and materials. Additionally, it is also utilized as a reagent in the formation of various heterocyclic compounds. Due to its versatile applications in the field of chemistry and pharmacology, 2,3-Quinoxalinedione,1,4-dihydro-,monohydrazone(9CI) is a valuable chemical compound with significant potential for further exploration and development.

InChI:InChI=1/C8H8N4O/c9-12-7-8(13)11-6-4-2-1-3-5(6)10-7/h1-4H,9H2,(H,10,12)(H,11,13)

Upstream product

• 30747-72-9 ethyl (3,4-dihydro-3-oxo-2-quinoxalinyl)phenyl acetate 
• 35015-91-9 3-amino-2(1H)-quinoxalinone 

Downstream Products

• 91895-51-1 4-Dimethylamino-1-ethyl[1,2,4]triazolo[4,3-a]quinoxaline 
• 160591-43-5 benzoic acid N'-(3-oxo-3,4-dihydro-quinoxalin-2-yl)-hydrazide 
• 943868-29-9 2-{(E)-[(3-oxo-3,4-dihydroquinoxalin-2-yl)hydrazono]methyl}benzoic acid 
• 1208247-49-7 3-[2-(2-bromocyclohexylidene)hydrazinyl]quinoxalin-2(1H)-one 
• 1208247-48-6 3-(2-cyclohexylidenehydrazinyl)quinoxalin-2(1H)-one 
• 1208247-50-0 3-[2-(2-chlorocyclohexylidene)hydrazinyl]quinoxalin-2(1H)-one 
• 1228259-30-0 3-(5-oxo-3-phenyl-4,5-dihydropyrazol-1-yl)quinoxalin-2(1H)-one 
• 1402546-82-0 C₁₇H₁₄N₄O₄ 

Relevant articles and documents

Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives

The reaction of o-phenylene diamine and ethyl oxamate is reinvestigated and led to 3-aminoquinoxalin-2(1H)-one rather than benzimidazole-2-carboxamide as was previously reported. The structure of the obtained quinoxaline has been confirmed by X-ray. The anti-tumor activity of synthesized quinoxalines 1-21 has been evaluated by studying their possible inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13- acetate (TPA). Among the studied compounds 1-21, compounds 12, 8, 13, 18, 17 and 19, respectively, demonstrated strong inhibitory effects on the EBV-EA activation without showing any cytotoxicity and their effects being stronger than that of a representative control, oleanolic acid. Furthermore, compound 12 exhibited a remarkable inhibitory effect on skin tumor promotion in an in vivo two-stage mouse skin carcinogenesis test using 7,12-dimethylbenz[a]anthracene (DMBA) as an initiator and TPA as a promoter. The result of the present investigation indicated that compound 12 might be valuable as a potent cancer chemopreventive agent. Moreover, the molecular docking into PTK (PDB: 1t46) has been done for lead optimization of the aforementioned compounds as potential PTK inhibitors.